IMPROVEMENT OF DENTAL RESINS: DECREASED TOXICITY AND IMPROVED BIOCOMPATIBILITY
UCLA Technology Available For Licensing

BACKGROUND:  Resin-based and resin-containing materials are routinely used in dental practices as direct filling materials, fissure sealing agents, and as bonding resins or resin cements for metal, porcelain, and resin inlays, veneers, crowns, and bridges. The use of resin-based materials will likely continue to increase in the future.

While the use of resin-containing materials is beneficial to the appearance of patients, these materials carry the risks of cytotoxicity and allergy. Most dental bonding technologies use primers containing the hydrophilic resins HEMA or TEGDMA. HEMA and TEGDMA have been shown to be a cause of these adverse effects due to the release of unpolymerized monomers in the surrounding tooth area, thereby triggering apoptosis or programmed cell death. Similarly, the adverse effects of bleaching agents on dental pulp and gingivae are well established. Therefore, methods for neutralizing the harmful effects of resin monomers and bleaching agents would be beneficial to current dental practices.

INNOVATION:  UCLA investigators have discovered that the presence of a confidential chemical inhibitor (CI) can inhibit HEMA, and TEGDMA-mediated apoptosis in various cell lines, including human and rat dental pulp stromal cells, immortalized human Oral Keratinocytes, human fibroblast cell line, the murine RAW 264.7 cell line, the human THP1 macrophage cell line, and the HaCaT skin keratinocyte cell line. Not only was cell death inhibited, but the presence of the CI also led to an increased viability and function of HEMA and TEGDMA treated cells. This in vitro data has been confirmed with in vivo rat models demonstrating that this CI can inhibit cell death induced by composites and bleaching systems. In addition, these rat models show the ability of this CI to restore the function of dental pulp stromal cells. The results indicate that CI prevents adverse effects mediated by HEMA, TEGDMA and bleaching agents.

POTENTIAL APPLICATIONS 

ADVANTAGES

Reference: UCLA Case No. 2005-379  

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@research.ucla.edu
NCD URL:   http://www.research.ucla.edu/tech/ucla05-379.htm

Lead Inventor: Anahid Jewett

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/oipa/industry

Copyright © 2006 The Regents of the University of California.

keywords: therapeutic treatment uclancd ucla technologies intellectual property patents technology transfer invention business card